Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing innovative targeted therapies for RAS-driven cancers. The company combines structure-based drug discovery expertise with deep capabilities in chemical biology, cancer pharmacology, and proprietary technologies to design small molecules for unconventional binding sites. Its research and development pipeline includes inhibitors that directly target RAS variants, known as RAS(ON) inhibitors, intended for use as standalone treatments, in combination with other RAS(ON) inhibitors, and alongside additional therapeutic agents.